Health Technology
Takeda Pharmaceutical Co., Ltd.
In the news
- Corporate Japan steps up sell-offs to trim fat Oct 14, 2019
- Blackstone sells 80 Japan condos to Allianz for $1.2bn Oct 5, 2019
- Corporate Japan sheds more cross-shareholdings Sep 5, 2019
- Japan's midsize drugmakers find niche in richer Southeast Asians Aug 25, 2019
- Global funds set sights on Japan property market Aug 11, 2019 See more articles on Takeda Pharmaceutical Co., Ltd.
Business Summary
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Financial Highlights
| Mar 2019 | JPY | USD |
| Revenue | 2,097.22B | 18,911.85M |
| Gross Profit | 1,242.84B | 11,207.41M |
| Operating income | 181,857M | 1,639.90M |
| Income before tax | 94,896M | 855.73M |
| Net income | 109,126M | 984.05M |
| EBITDA | 454,303M | 4,096.70M |
| Diluted EPS | 112.86 | 1.01 |
| Dividends Per Share | 180 | 1.62 |
| Total Assets | 13,872.32B | 125,331.55M |
| Total liabilities | 8,708.73B | 78,680.35M |
| Total equity | 5,159.58B | 46,615.00M |
| Operating cash flow | 302,609M | 2,728.79M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 1,777.82B | 1,807.37B | 1,732.05B | 1,770.53B | 2,097.22B |
| Gross Profit | 1,134.39B | 1,161.84B | 1,017.65B | 1,148.86B | 1,242.84B |
| Operating income | 195,804M | 175,770M | 86,972M | 195,320M | 181,857M |
| Income before tax | -145,437M | 120,539M | 143,346M | 217,205M | 94,896M |
| Net income | -145,775M | 80,166M | 114,940M | 186,886M | 109,126M |
| EBITDA | 387,391M | 353,275M | 258,398M | 377,447M | 454,303M |
| Diluted EPS | -185.37 | 101.71 | 146.25 | 237.55 | 112.86 |
| Dividends Per Share | 180 | 180 | 180 | 180 | 180 |
| Total Assets | 4,296.19B | 3,824.08B | 4,346.79B | 4,106.46B | 13,872.32B |
| Total liabilities | 2,090.01B | 1,812.88B | 2,397.82B | 2,089.05B | 8,708.73B |
| Total equity | 2,137.04B | 1,948.69B | 1,894.26B | 1,997.42B | 5,159.58B |
| Operating cash flow | 183,441M | 26,552M | 260,067M | 379,600M | 302,609M |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 16,183.14M | 15,050.91M | 15,994.93M | 15,974.84M | 18,911.85M |
| Gross Profit | 10,326.11M | 9,675.22M | 9,397.74M | 10,365.80M | 11,207.41M |
| Operating income | 1,782.36M | 1,463.72M | 803.15M | 1,762.30M | 1,639.90M |
| Income before tax | -1,323.88M | 1,003.78M | 1,323.75M | 1,959.76M | 855.73M |
| Net income | -1,326.95M | 667.58M | 1,061.43M | 1,686.20M | 984.05M |
| EBITDA | 3,526.33M | 2,941.89M | 2,386.22M | 3,405.56M | 4,096.70M |
| Diluted EPS | -1.68 | 0.84 | 1.35 | 2.14 | 1.01 |
| Dividends Per Share | 1.63 | 1.49 | 1.66 | 1.62 | 1.62 |
| Total Assets | 35,823.98M | 34,023.62M | 39,009.18M | 38,612.71M | 125,331.55M |
| Total liabilities | 17,427.69M | 16,129.56M | 21,518.70M | 19,643.19M | 78,680.35M |
| Total equity | 17,819.86M | 17,337.88M | 16,999.56M | 18,781.60M | 46,615.00M |
| Operating cash flow | 1,669.82M | 221.11M | 2,401.63M | 3,424.99M | 2,728.79M |
Valuation Measures
| Mar 2019 | |
| PER | 39.83 |
| ROA | 1.21% |
| ROE | 3.04% |
| Operating margin | 8.67% |
| Profit margin | 5.20% |
Key executives
- President, CEO & Representative Director: Christophe Weber
- Chief Financial Officer: Costa Saroukos
- Director, Chief Medical & Scientific Officer: Andrew S. Plump
- Executive Officer & Global General Counsel: Yoshihiro Nakagawa
- Global Human Resources Officer & Executive Officer: David Osborne
Shareholders
- Nomura Asset Management Co., Ltd. (3.4%)
- Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.3%)
- BlackRock Fund Advisors (3.1%)
- Asset Management One Co., Ltd. (2.7%)
- Causeway Capital Management LLC (2.6%)
- Nippon Life Insurance Co. (2.2%)
- The Vanguard Group, Inc. (1.9%)
- Capital Research & Management Co. (World Investors) (1.7%)
- Nikko Asset Management Co., Ltd. (1.5%)
- State Street Global Advisors Ltd. (1.5%)
Contact Details
- Website:http://www.takeda.co.jp
- Address: 4-1-1 Dosho-machi, Chuo-Ku, Osaka, 540-8645, Japan
- Phone: +81.6.6204.2111
Related Companies
- Takeda Pharmaceuticals Co. Ltd. /Primary Care Portfolio Bus/
- Takeda Pharmaceutical Co. Ltd. /Non Core Assets/
- Takeda Re Insurance AG
- Takeda Pharmaceutical Co. Ltd. /Tachosil Business/
- Plasmapunkt Favoriten GmbH
- Takeda Malaysia Sdn. Bhd.
- Takeda Pharmaceutical Co. Ltd. /Latam Bus/
- Takeda Oranienburg Real Estate GmbH & Co. KG
- Takeda Consumer Healthcare Co. Ltd.
- Takeda Pharmaceutical Director Incentive Plan
- Takeda Pharmaceutical Employee Incentive Plan
- Oy Leiras Takeda Pharmaceuticals AB
- Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
- Takeda Pharma AB
- Takeda Development Center Americas, Inc.
- Takeda Ukraine LLC
- Takeda Pharmaceuticals Taiwan Ltd.
- Takeda SRL
- Takeda Hellas SA
- Takeda Christiaens SCA/CVA
- Takeda Belgium SCA/CVA
- Takeda Vaccines Pte Ltd.
- Takeda Pharmaceuticals (Asia Pacific) Pte Ltd.
- Takeda Development Center Asia Pte Ltd.
- Takeda Pharma Sp zoo
- Takeda Mexico SA de CV
- Takeda Kazakhstan LLP
- Takeda Pharmaceuticals Korea Co., Ltd.
- Takeda Farmaceutica Espana SA
- Takeda Pharma Ltda.
Competitors
- Sanofi
- AstraZeneca PLC
- Grifols, S.A. Class A
- Celgene Corporation
- Amicus Therapeutics, Inc.
- Novartis AG
- Pfizer Inc.
- Merck & Co., Inc.
- Johnson & Johnson
- CSL Limited
- AbbVie, Inc.
- Bristol-Myers Squibb Company
- Bayer AG
- Allergan plc
- Roche Holding AG
- UCB S.A.
- Biotest AG Pref
- Merck KGaA
- Swedish Orphan Biovitrum AB
- Novo Nordisk A/S Class B
- ISU Abxis Co., Ltd.
- Dr. Reddy's Laboratories Ltd.
- Green Cross Corporation
- Ipsen SA
- MorphoSys AG
- Amgen Inc.
- Eli Lilly and Company
- Hanmi Pharmaceutical Co., Ltd.
- Daewoong Co., Ltd.
- Faes Farma, S.A.
Copyright © 2019 FactSet Research Systems Inc. All rights reserved.
Last Updated on 23 Oct, 2019